Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Ischaemia-reperfusion
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatIschaemia-reperfusionOther / unspecifiedSprague-Dawleyn = 46 rats total: injured n=9, injured plus PEUU-Tac n=14, inj…Local trans-dural application, matrix wrapped around the optic nerve injury site and sutured to itself and the sheath; systemic comparator given intraperitoneally2 mm by 5 mm section of the 10 mg tacrolimus PEUU matrix ap…Applied immediately after the 10 s clamp during the same surgery; systemic comp…
Model: Acute optic nerve ischaemia: right optic nerve clamped approximately 2 mm behind the globe for 10 s with a Yasargil aneurysm clip; a subset had the nerve sheath fenestrated with a 1 to 2 mm incision at the clamp site
PEUU-Tac delivered tacrolimus trans-durally at tissue levels comparable to daily systemic dosing while keeping blood levels very low (0.15 plus or minus 0.05 ng/mL at 14 days versus 28 plus or minus 4 ng/mL systemic), reduced injury-induced GFAP and increased GAP-43, although optic nerve tissue con…
Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.